ERBB2 and neoplasm: Clinical data of adoptive T-cell strategies are lacking for patients with HER2+ MBC, likely as a function of increased cost, needs for specialized centers for treatment development, and concerns related to off-target AEs secondary to the broad stimulation of the immune system against non-tumor specific antigens.